Carl J Atkinson

US Patent:

20210388080, Dec 16, 2021

Filed:

Apr 12, 2021

Appl. No.:

17/228279

Inventors:

- Denver CO, US
- Charleston SC, US
- Washington DC, US
Joshua M. Thurman - Greenwood Village CO, US
Carl Atkinson - Mount Pleasant SC, US
Liudmila Kulik - Aurora CO, US

International Classification:

C07K 16/28
A61K 39/395
A61K 45/06

Abstract:

The present invention provides targeted delivery methods and constructs for treating inflammatory diseases and/or detecting in vivo tissue injuries in an individual. The targeted delivery approach utilizes an antibody that recognizes an epitope found to be present at sites of inflammation. The invention also provides methods of inhibiting complement-driven inflammation in the eye in an individual, comprising administering to the individual an antibody or a fragment thereor or compositions thereof, wherein the antibody or fragment thereof specifically binds to Annexin IV or phospholipid. Also provided are related methods of treating a complement-associated ocular disease or an ocular disease involving oxidative damage. Additionally, the invention provides methods of detecting complement-mediated injury in an eye tissue of an individual, comprising administering to the individual a construct or compositions thereof, wherein the construct comprises (a) an antibody or fragment thereof that specifically binds to Annexin IV or phospholipid; and (b) a detectable moiety.

US Patent:

20160083469, Mar 24, 2016

Filed:

Jul 23, 2015

Appl. No.:

14/807521

Inventors:

- Denver CO, US
- Charleston SC, US
- Washington DC, US
Joshua M. Thurman - Greenwood Village CO, US
Carl Atkinson - Mount Pleasant SC, US
Liudmila Kulik - Aurora CO, US

International Classification:

C07K 16/28
A61K 45/06
A61K 39/395

Abstract:

The present invention provides targeted delivery methods and constructs for treating inflammatory diseases and/or detecting in vivo tissue injuries in an individual. The targeted delivery approach utilizes an antibody that recognises an epitope found to be present at sites of inflammation. The invention also provides methods of inhibiting complement-driven inflammation in the eye in an individual, comprising administering to the individual an antibody or a fragment thereof or compositions thereof, wherein the antibody or fragment thereof specifically binds to Annexin IV or phospholipid. Also provided are related methods of treating a complement-associated ocular disease or an ocular disease involving oxidative damage. Additionally, the invention provides methods of detecting complement-mediated injury in an eye tissue of an individual, comprising administering to the individual a construct or compositions thereof, wherein the construct comprises (a) an antibody or fragment thereof that specifically binds to Annexin IV or phospholipid; and (b) a detectable moiety.